79279-08-6

Basic information

• Product Name: Bifendate Impurity G
• Synonyms: Bifendate Impurity G;Bifendate Impurity 5;(7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-diyl)dimethanol;Bicyclol Impurity E
• CAS NO: 79279-08-6
• Molecular Formula: C₁₈H₁₈O₈
• Molecular Weight: 362.33072
• Mol File: 79279-08-6.mol

Chemical Properties

• Boiling Point: 611.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.433±0.06 g/cm3(Predicted)
• PKA: 13.57±0.10(Predicted)
• CAS DataBase Reference: Bifendate Impurity G(CAS DataBase Reference)
• NIST Chemistry Reference: Bifendate Impurity G(79279-08-6)
• EPA Substance Registry System: Bifendate Impurity G(79279-08-6)

Safety Data

• Hazardous Substances Data: 79279-08-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Bifendate Impurity G is used as a synthetic intermediate for Schisandrin C, a compound with potential health benefits.
Bifendate Impurity G is also used as an anti-HBV drug for the treatment of chronic hepatitis B, helping to manage and control the viral infection.

Upstream product

• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 123685-25-6 5-methoxy-3,4-dihydroxy-2-bromobenzoic acid methyl ester 
• 143883-73-2 2-bromo-5-O-methyl gallic acid 
• 3934-84-7 3,4-dihydroxy-5-methoxybenzoic acid 
• 81474-46-6 4-bromo-7-methoxybenzo[1,3]dioxole-5-carboxylic acid methyl ester 
• 111897-19-9 DDB 

Downstream Products

• 143883-74-3 6-phenyl-3,9-dimethoxy-1,2-methylenedioxy-10,11-methylenedioxy-6,7-dihydro-5H-dibenz[c,e]azepine 
• 143883-75-4 6-(m-chlorophenyl)-3,9-dimethoxy-1,2-methylenedioxy-10,11-methylenedioxy-6,7-dihydro-5H-dibenz(c,e)azepin 
• 1377829-20-3 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)-bis(methylene) bis(4-cyanobenzoate) 
• 1377829-18-9 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)-bis(methylene) bis(3,4,5-trimethoxybenzoate) 
• 1377829-14-5 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)bis(methylene) dibenzoate 
• 1377829-15-6 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)bis(methylene) bis(4-methylbenzoate) 
• 1377829-16-7 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)-bis(methylene) bis(4-methoxybenzoate) 
• 1377829-19-0 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)-bis(methylene) bis(4-nitrobenzoate) 
• 1377829-17-8 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)-bis(methylene) bis(3,4-dimethoxybenzoate) 
• 1377829-09-8 (4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-diyl)-bis(methylene) dicyclohexanecarboxylate 

Relevant articles and documents

HDAC inhibitors and application thereof

The invention discloses histone deacetylase (HDAC) inhibitors. The HDAC inhibitors are bifendate derivatives shown as general formulas (I)-(IV) and pharmaceutically acceptable salts or deuterated substances of the bifendate derivatives. The invention also

Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors

As a continuation of previous research, fifteen bifendate derivatives bearing 6,7-dihydro-dibenzo [c,e]azepine scaffold were synthesized and evaluated as P-gp-medicated multidrug resistance (MDR) reversal agents. Biological evaluation indicated that compounds 6k and 9c more potently reversed P-gp-mediated MDR than bifendate and verapamil (VRP) by blocking P-gp mediated drug efflux function and not by decreasing P-gp expression in K562/A02 MDR cells. Interestingly, wound-healing and chamber migration assay showed that 6k and 9c could significantly attenuate the migration of MDA-MB-231 cells. Notably, 6k and 9c could markedly suppress the invasive activity of MDA-MB-231 cells, thus displayed potential anti-metastasis activity. Preliminary mechanism studies indicated that the anti-metastasis activity of 6k and 9c was associated with their inhibitory effect on the activity and expression of MMP-2 and MMP-9. These results, together with the MDR reversal results indicated that compounds 6k and 9c might be promising leads for developing novel anti-cancer agents with P-gp and tumor metastasis inhibitory activities.

Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors

Overexpression of P-glycoprotein (P-gp) is one of the major problems in successful treatment of cancers. To find new P-gp inhibitors, a series of bifendate (DDB) derivatives bearing dibenzo[c,e]azepine scaffold were synthesized and evaluated. Compound 4i more potently reversed P-gp-mediated multidrug resistance (MDR) than DDB and verapamil (VRP) by blocking P-gp mediated drug efflux function and increasing drug accumulation in K562/A02 MDR cells, and persisted longer chemo-sensitizing effect (>24 h) than VRP (6 h). Interestingly, unlike VRP, 4i showed no stimulation on the P-gp ATPase activity, suggesting it is not a substrate of P-gp. Given the low intrinsic cytotoxicity of 4i in vitro, it may represent a promising lead for developing therapeutics targeting P-gp-mediated MDR in combinational cancer chemotherapy.

Synthesis and antihepatotoxicity of some Wuweizisu analogues

A preparation of dimethyl 4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (VII) was readily achieved. It provided the advantages of specificity, simplicity, and efficiency in reactions. 6-Phenyl-3,9-dimethoxy-1,2-methylenedioxy-10,11-methylenedioxy-6,7- dihydro-5H-dibenz(c, e)azepin (X) was successfully synthesized from VII (DDB) and its liver-protective property proved to be more effective than DDB and silymarin in the in vitro test of carbon tetrachloride-induced damage of primary cultured rat hepatocytes.